Last $62.65 USD
Change Today +0.07 / 0.11%
Volume 1.1M
CBST On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
NASDAQ GS
As of 8:10 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

cubist pharmaceuticals inc (CBST) Snapshot

Open
$62.56
Previous Close
$62.58
Day High
$65.00
Day Low
$61.83
52 Week High
02/28/14 - $82.12
52 Week Low
07/25/13 - $53.06
Market Cap
4.7B
Average Volume 10 Days
1.0M
EPS TTM
$0.82
Shares Outstanding
75.3M
EX-Date
--
P/E TM
76.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for CUBIST PHARMACEUTICALS INC (CBST)

cubist pharmaceuticals inc (CBST) Related Businessweek News

View More BusinessWeek News

cubist pharmaceuticals inc (CBST) Details

Cubist Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. The company offers CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; DIFICID for the treatment of clostridium difficile-associated diarrhea (CDAD); and ENTEREG (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. It also develops Tedizolid Phosphate, a novel antibiotic product candidate for the treatment of serious gram-positive bacterial infections; and Ceftolozane/tazobactam, an I.V. antibacterial product candidate for the treatment of certain serious gram-negative bacterial infections in the hospital. In addition, the company develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; and Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain. Cubist Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Lexington, Massachusetts.

873 Employees
Last Reported Date: 02/25/14
Founded in 1992

cubist pharmaceuticals inc (CBST) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $750.0K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $358.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $475.0K
Senior Vice President and General Manager of ...
Total Annual Compensation: $440.2K
Compensation as of Fiscal Year 2013.

cubist pharmaceuticals inc (CBST) Key Developments

Cubist Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Cubist Pharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, total revenue, net was $294.398 million against $258.779 million a year ago. Operating income was $42.171 million against $6.678 million a year ago. Income before income taxes was $28.036 million against $21.395 million a year ago. Net income was $24.028 million or $0.30 per diluted share against $15.242 million or $0.23 per diluted share a year ago. Non-GAAP adjusted operating income was $41.353 million against $51.270 million a year ago. Non-GAAP net income was $19.044 million or $0.23 per diluted share against $33.022 million or $0.42 per diluted share a year ago. For the six months, total revenue, net was $446.907 million against $429.162 million a year ago. Operating income was $70.477 million against $37.864 million a year ago. Income before income taxes was $42.255 million against $24.984 million a year ago. Net income was $48.261 million or $0.61 per diluted share against $21.330 million or $0.32 per diluted share a year ago. Non-GAAP adjusted operating income was $60.147 million against $93.502 million a year ago. Non-GAAP net income was $26.845 million or $0.34 per diluted share against $59.194 million or $0.77 per diluted share a year ago.

Cubist Pharmaceuticals Inc. to Report Q2, 2014 Results on Jul 22, 2014

Cubist Pharmaceuticals Inc. announced that they will report Q2, 2014 results at 4:00 PM, US Eastern Standard Time on Jul 22, 2014

Cubist Pharmaceuticals Inc., Q2 2014 Earnings Call, Jul 22, 2014

Cubist Pharmaceuticals Inc., Q2 2014 Earnings Call, Jul 22, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBST:US $62.65 USD +0.07

CBST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €10.80 EUR -0.06
Ironwood Pharmaceuticals Inc $15.40 USD +0.35
Salix Pharmaceuticals Ltd $132.26 USD -0.09
Synergy Health PLC 1,356 GBp -4.00
Theravance Inc $23.88 USD -1.44
View Industry Companies
 

Industry Analysis

CBST

Industry Average

Valuation CBST Industry Range
Price/Earnings 100.0x
Price/Sales 4.2x
Price/Book 3.2x
Price/Cash Flow 563.7x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUBIST PHARMACEUTICALS INC, please visit www.cubist.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.